Product Information

HUMIRA(CF) PEN 80 MG/0.8 ML is a brand product labeled by AbbVie Inc., priced at $6734.1227 per EA under NDC 00074012402. Its NADAC has been published 166 times since Jun 21, 2023.

HUMIRA(CF) PEN 80 MG/0.8 ML

Adalimumab
$6734.1227per EA

Manufacturer

AbbVie Inc.

NDC

00074012402

Classification

Brand

Dosage Form

KIT

Effective Date

8/19/2026

Approval Type

Biologic (BLA)

FDA Application

BLA125057

On Market Since

4/21/2017

Price Statistics

The NADAC for HUMIRA(CF) PEN 80 MG/0.8 ML has been published 166 times since Jun 21, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$6734.1227 per EA
All-time high$6734.5168 (Dec 10, 2025)
All-time low$6721.8790 (Jun 21, 2023)
52-week high$6734.5168
52-week low$6729.6518
Median price$6728.6926
Average price$6727.9782
Largest weekly change+0.1% (Apr 17, 2024)
Weeks tracked166
Tracking sinceJun 21, 2023

Price History

1W

+0.0%

1M

+0.0%

3M

+0.0%

6M

+0.0%

1Y

+0.0%

3Y

+0.2%

5Y

N/A

All

+0.2%

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 50% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 50%

1 alternative • Same active ingredient

Related Drugs

Same classification

No related drugs found.

Frequently asked questions

What is the NADAC price of HUMIRA(CF) PEN 80 MG/0.8 ML?

The current National Average Drug Acquisition Cost (NADAC) for HUMIRA(CF) PEN 80 MG/0.8 ML, manufactured by AbbVie Inc., is $6734.1227 per EA (NDC 00074012402), effective Aug 19, 2026.

How has the price of HUMIRA(CF) PEN 80 MG/0.8 ML changed over time?

Over the history we have for it, the NADAC for HUMIRA(CF) PEN 80 MG/0.8 ML has held within roughly two percent of its current level. It has been tracked across 166 weekly CMS publications since Jun 21, 2023.

What are the highest and lowest recorded NADAC prices for HUMIRA(CF) PEN 80 MG/0.8 ML?

Since Jun 21, 2023, the NADAC for HUMIRA(CF) PEN 80 MG/0.8 ML has ranged from a low of $6721.8790 (Jun 21, 2023) to a high of $6734.5168 (Dec 10, 2025), with a median of $6728.6926 per EA.

Are there cheaper alternatives to HUMIRA(CF) PEN 80 MG/0.8 ML?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, HUMIRA(CF) 20 MG/0.2 ML SYRINGE, is $3366.1230 per EA — about 50% below HUMIRA(CF) PEN 80 MG/0.8 ML.

Who manufactures HUMIRA(CF) PEN 80 MG/0.8 ML?

HUMIRA(CF) PEN 80 MG/0.8 ML (NDC 00074012402) is labeled by AbbVie Inc., and CMS classifies it as a brand product.